Echo IQ Limited (ASX: EIQ) is an Australian AI and medical technology company focused on improving decision-making in cardiology. Its lead product, EchoSolv HF, is a heart failure clinical decision support software designed to assist clinicians in detecting heart failure using echocardiogram data. The Company’s recent announcements outline the completion of clinical validation with the Mayo Clinic Platform and the subsequent formal lodgement of an FDA 510(k) submission in the

Echo IQ Limited (ASX: EIQ), based in Sydney, has released new clinical insights presented at the AHA Scientific Sessions 2025 in New Orleans, highlighting the growing medical need and commercial opportunity for EchoSolv AS, the Company’s AI-powered decision-support tool for severe aortic stenosis (AS).

Echo IQ Limited (ASX: EIQ) is pushing its cardiology decision-support platform into the heart failure space, with its EchoSolv HF algorithm now validated through the Mayo Clinic Platform’s independent “Validate” program in the United States. The Company, based in Sydney with operations anchored out of Western Australia, has completed what it describes as the final clinical requirement ahead of a planned FDA 510(k) submission for EchoSolv HF – a heart failure decision-support